Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Tainuo Signs $42.5 Million China Deal for Knee Osteoarthritis Pain Treatment

publication date: Apr 1, 2020

HK Tainuo and Jiangsu Tainuo signed a $42.5 million agreement to acquire greater China rights to a treatment for knee osteoarthritis pain from Flexion Therapeutics of the US. Zilretta was approved in the US in 2017 as an extended-release intra-articular therapy for patients with knee pain. HK Tainuo will make an upfront payment of $10 million to Flexion and be responsible for up to $32.5 million in milestones along with China development activities for Zilretta. Tainuo is a subsidiary of China Shijiazhuang Pharma. More details....

Stock Symbols: (NSDQ: FLXN) (HK: 1093)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.